EPIRUS Biopharmaceuticals Valuation

EPIRUS Biopharmaceutica Investor Information

The company has price-to-book (P/B) ratio of 0.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. EPIRUS Biopharmaceuticals recorded a loss per share of 2.53. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 16th of July 2014. Based on the key measurements obtained from EPIRUS Biopharmaceutica's financial statements, EPIRUS Biopharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.

EPIRUS Biopharmaceutica Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. EPIRUS Biopharmaceutica has an asset utilization ratio of 0.97 percent. This connotes that the Company is making $0.009701 for each dollar of assets. An increasing asset utilization means that EPIRUS Biopharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

EPIRUS Biopharmaceutica Profitability Analysis

The company reported the revenue of 701 K. Net Loss for the year was (52.19 M) with profit before overhead, payroll, taxes, and interest of 576 K.

Investing in growth stocks can be very risky. If the company such as EPIRUS Biopharmaceutica does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.